Low Phytanic Acid-Concentrated DHA Prevents Cognitive Deficit and Regulates Alzheimer Disease Mediators in an ApoE−/− Mice Experimental Model

Alzheimer’s disease (AD) is the main cause of dementia and cognitive impairment. It has been associated with a significant diminution of omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) levels in the brain. Clinical trials with DHA as a treatment in neurological diseases have shown inco...

ver descrição completa

Detalhes bibliográficos
Autores: Ruiz-Roso Guerra, María Belén, Echeverry Alzate, Víctor, Ruiz-Roso Calvo De La Mora, Baltasar, Quintela, José, Ballesteros Rodrigálvarez, Sandra María, Lahera Julia, Vicente, Heras Jiménez, Natalia De Las, López Moreno, José Antonio, Martín Fernández, Beatriz
Formato: artículo
Fecha de publicación:2018
País:España
Recursos:Universidad Complutense de Madrid (UCM)
Repositorio:Docta Complutense
Idioma:inglés
OAI Identifier:oai:docta.ucm.es:20.500.14352/19079
Acesso em linha:https://hdl.handle.net/20.500.14352/19079
Access Level:acceso abierto
Palavra-chave:Alzheimer’s
DHA
ApoE -/-
Phytanic acid
Inflammation
Neuroprotection
Oxidation
Neurociencias (Medicina)
2490 Neurociencias
Descrição
Resumo:Alzheimer’s disease (AD) is the main cause of dementia and cognitive impairment. It has been associated with a significant diminution of omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) levels in the brain. Clinical trials with DHA as a treatment in neurological diseases have shown inconsistent results. Previously, we reported that the presence of phytanic acid (PhA) in standard DHA compositions could be blunting DHA’s beneficial effects. Therefore, we aimed to analyze the effects of a low PhA-concentrated DHA and a standard PhA-concentrated DHA in Apolipoprotein E knockout (ApoE

Registos relacionados